Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14

The involvement of cell surface nucleolin in the initiation of CCR6 signaling in human hepatocellular carcinoma

(2015) Wei Qiu et al.   MEDICAL ONCOLOGY

A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis

(2015) Na Shen et al.   Oncotarget

Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy

(2014) XiaoDong Guo et al.   Diagnostic Pathology

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

(2013) Jonathan E. Rosenberg et al.   INVESTIGATIONAL NEW DRUGS

Cell-Specific, Activatable, and Theranostic Prodrug for Dual-Targeted Cancer Imaging and Therapy

(2011) Santimukul Santra et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Aptamers as therapeutics

(2010) Anthony D. Keefe et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular targeted therapies in hepatocellular carcinoma

(2008) Josep M. Llovet et al.   HEPATOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection

(2007) Klaus Juergen Schmitz et al.   JOURNAL OF HEPATOLOGY